Evidence map›Paper›PMID 40096722›Full record

Observational studyLa Tunisie medicale2025

Rania Hammami, Aymen Dammak, Faiza Safi, Nouha Ktata, Hanen Maamri, Mouna Baklouti, Fadhila Issaoui, Nejah Ben Halima, Olfa Chakroun, Jihen Jdidi

Abstract readComparative StudyEnglish AbstractObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in La Tunisie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rania HammamiSfax University, University of Medicine, Cardiology Department, Military University Hospital of Sfax, Tunisia.
Aymen DammakSfax University, University of Medicine, Cardiovascular surgery Department, Habib Bourguiba Hospital, Tunisia.
Faiza SafiSfax University, University of Medicine, Cardiology Department, Hedi Chaker Hospital, Sfax, Tunisia.
Nouha KtataSfax University, University of Medicine, Epidemiology Department Hedi Chaker Hospital, Sfax, Tunisia.
Hanen MaamriSfax University, University of Medicine, Epidemiology Department Hedi Chaker Hospital, Sfax, Tunisia.
Mouna BakloutiSfax University, University of Medicine, Epidemiology Department Hedi Chaker Hospital, Sfax, Tunisia.
Fadhila IssaouiSousse University, University of Medicine, Cardiology Department, Farhat Hached Hospital, Sfax, Tunisia.
Nejah Ben HalimaSousse University, University of Medicine, Cardiology Department, Farhat Hached Hospital, Sfax, Tunisia.
Olfa ChakrounSfax University, University of Medicine, Emergency Department, University Hospital Habib Bourguiba Sfax, Sfax, Tunisia.
Jihen JdidiSfax University, University of Medicine, Epidemiology Department Hedi Chaker Hospital, Sfax, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are no clear data on the incidence and predictors of arterial and venous thromboembolic (TE) events in COVID-19 ambulatory patients.

aimWe conducted this study to analyze thromboembolic complications in this setting and to compare the efficacy and safety of Rivaroxaban to LMWHs as a thromboprophylaxis treatment.

methodsThis is an observational study including COVID-19 patients treated on an outpatient basis. We analysed the predictors of thromboembolic events.

resultsWe included 2089 patients with COVID19 managed on an outpatient basis during the period from October 01, 2020 to December 31, 2021. The mean age of our patients was 43±16 years. The incidence of venous and arterial TE complications was 0.9%. Predictive factors for arteriovenous thromboembolic complications were hormonal contraception (OR=23), moderate clinical form (OR=3.5), recent surgery or miscarriage in the month preceding COVID-19 (OR=9.2) and CT signs of COVID-19 (OR=4.9). In contrast, physical activity proved to be a protective factor. Thromboprophylaxis was prescribed in 22.5% of cases: LMWH in 18.1%, Rivaroxaban in 3.7% and a combination of the two molecules successively in 0.6% of patients. There was no statistical difference in thromboembolic or major bleeding complications between the Rivaroxaban and LMWH groups.

conclusionOur study showed that the incidence of thromboembolic complications is very low in Covid-19 ambulatory patients.

Indexed as

COVID-19ThromboembolismAdultAgedAmbulatory CareAnticoagulantsFemaleHeparin, Low-Molecular-WeightHumansIncidenceMaleMiddle AgedRisk FactorsRivaroxabanSARS-CoV-2AnticoagulantsHeparin, Low-Molecular-WeightRivaroxabanCOVID-19hemorrhagic eventsLow Molecular Weight HeparinRivaroxabanthromboembolic events

Identifiers

PMID40096722
PMCPMC12034356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.